Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2014

View Archived Issues

Chemical modification of a marketed HIV protease inhibitor leads to new immunomodulatory agent

Mitochondrial-targeted nanoparticle drug delivery to overcome anticancer drug resistance

MYOS and Cloud Pharmaceuticals to develop drugs targeting sarcopenia and cachexia

Hopp acquires Lohmann Therapie-Systeme shares from Novartis and BWK

Celgene to initiate phase II study of CC-220 in cutaneous sarcoidosis

Novel tau aggregation inhibitors for the treatment of tauopathies

Novel O-GlcNAcase inhibitors prepared by Alectos Therapeutics and Merck & Co.

AbbVie's multidrug regimen for HCV evaluated in patients with HIV co-infection

OriBase Pharma discloses novel multi kinase inhibitors

Hanmi signs contract with Actavis for Hyalrheuma

Sandoz to commercialize Anacor's Kerydin in U.S.

Japan Tobacco describes new HIV integrase inhibitors

Ube Industries discloses novel LPA1 receptor antagonists

Merck & Co. designs novel adenosine receptor antagonists for PD

Nippon Zoki synthesizes novel agents for neuropathic pain

MARCH8 protein blocks HIV-1 infection

Daiichi Sankyo to test DS-5573a in patients with solid tumors

Strides Arcolab makes strategic investment in U.S. biosimilar developer Oncobiologics

Sanofi plans first-in-human study of SAR-408701 for advanced solid tumors

Regulus Therapeutics' anti-miR-21 oligonucleotide awarded FDA orphan drug status for Alport syndrome

Genocea initiates phase II study of GEN-003 HSV-2 immunotherapy

Dipexium Pharmaceuticals initiates pivotal phase III trials of topical peptide antibiotic

Pivotal study of PRT-201 for hemodialysis vascular access in patients with chronic kidney disease

FDA grants breakthrough therapy designation to Aduro's pancreatic cancer combination immunotherapy

FDA grants priority review to Avastin sBLA in ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...